8.05
7.76%
0.58
Pre-mercato:
8.06
0.010
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$7.47
Aprire:
$7.61
Volume 24 ore:
4.73M
Relative Volume:
1.77
Capitalizzazione di mercato:
$585.35M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-4.9387
EPS:
-1.63
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-15.44%
1M Prestazione:
+17.01%
6M Prestazione:
+0.12%
1 anno Prestazione:
+206.08%
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ALT | 8.05 | 585.35M | 409.00K | -101.35M | -71.49M | -1.63 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
2024-01-24 | Iniziato | Goldman | Neutral |
2023-03-22 | Downgrade | Goldman | Buy → Neutral |
2022-12-01 | Iniziato | Goldman | Buy |
2021-12-29 | Ripresa | Jefferies | Buy |
2021-06-02 | Iniziato | H.C. Wainwright | Buy |
2021-02-11 | Iniziato | Guggenheim | Buy |
2020-12-14 | Iniziato | Jefferies | Buy |
2020-11-12 | Reiterato | B. Riley Securities | Buy |
2020-09-25 | Iniziato | B. Riley FBR | Buy |
2020-08-14 | Iniziato | Evercore ISI | Outperform |
2020-07-31 | Iniziato | Piper Sandler | Overweight |
2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
2020-02-24 | Ripresa | ROTH Capital | Buy |
2019-07-19 | Iniziato | ROTH Capital | Buy |
2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
(ALT) Trading Report - Stock Traders Daily
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha
Altimmune Unusual Options Activity For November 13 - Benzinga
Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha
Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey
UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq
GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India
Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance
Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart
Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks
Altimmune Stock Rallies 30% on Updates - citybiz
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com
Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks
UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Altimmune Appoints Greg Weaver as CFO - citybiz
Altimmune Appoints Chief Financial Officer - Contract Pharma
Altimmune says ‘something raised attention of FDA’ - TipRanks
Altimmune appoints Greg Weaver as CFO - TipRanks
Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St
Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha
Altimmune advances obesity treatment into Phase 3 trials - Investing.com India
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times
Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):